Peloton Therapeutics

Peloton Therapeutics is involved in discovering and developing novel drugs for cancer treatments. Peloton Therapeutics was founded with the aim of capitalizing on untapped biomedical breakthroughs. By engaging in productive collaborations with world-class scientific visionaries, Peloton has been able to create innovative medicines to address the unmet needs of patients afflicted with life-threatening diseases.Peloton’s lead investigational therapy, PT2385, is in Phase 1 clinical development as a selective, potent, and orally bioavailable treatment for advanced clear cell renal cell carcinoma (ccRCC). Preclinical data supports the application of PT2385 in other oncology indications such as glioblastoma. In addition to its clinical program, Peloton has a strong discovery pipeline. ACSS2 is a metabolic target that is important for tumor growth under conditions of nutrient stress. In addition to its internal scientific expertise, Peloton has successfully cultivated relationships with several investigators at leading academic institutions to gain direct access to cutting-edge science.